Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept - PubMed (original) (raw)
Comparative Study
Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept
C M Roe et al. Neurology. 2010.
Abstract
Objective: Several factors may influence the relationship between Alzheimer disease (AD) lesions and the expression of dementia, including those related to brain and cognitive reserve. Other factors may confound the association between AD pathology and dementia. We tested whether factors thought to influence the association of AD pathology and dementia help to accurately identify dementia of the Alzheimer type (DAT) when considered together with amyloid imaging.
Methods: Participants with normal cognition (n = 180) and with DAT (n = 25), aged 50 years or older, took part in clinical, neurologic, and psychometric assessments. PET with the Pittsburgh compound B (PiB) tracer was used to measure brain amyloid, yielding a mean cortical binding potential (MCBP) reflecting PiB uptake. Logistic regression was used to generate receiver operating characteristic curves, and the areas under those curves (AUC), to compare the predictive accuracy of using MCBP alone vs MCBP together with other variables selected using a stepwise selection procedure to identify participants with DAT vs normal cognition.
Results: The AUC resulting from MCBP alone was 0.84 (95% confidence interval [CI] = 0.73-0.94; cross-validated AUC = 0.80, 95% CI = 0.68-0.92). The AUC for the predictive equation generated by a stepwise model including education, normalized whole brain volume, physical health rating, gender, and use of medications that may interfere with cognition was 0.94 (95% CI = 0.90-0.98; cross-validated AUC = 0.91, 95% CI = 0.85-0.96), an improvement (p = 0.025) over that yielded using MCBP alone.
Conclusion: Results suggest that factors reported to influence associations between AD pathology and dementia can improve the predictive accuracy of amyloid imaging for the identification of symptomatic AD.
Figures
Figure 1 Flow diagram for participant inclusion CDR = Clinical Dementia Rating; DAT = dementia of the Alzheimer type; GDS = Geriatric Depression Scale; nWBV = normalized whole brain volume; PiB = Pittsburgh Compound B. *Participation was tied to recruitment goals for PET PiB imaging studies.
Figure 2 Receiver operating characteristic (ROC) curves for all model building steps in the stepwise analysis Model step 1 is the ROC curve with mean cortical binding potential (MCBP) as the sole predictor of a dementia of the Alzheimer type diagnosis. Steps 2–6 show the area under the ROC curve with the addition of each additional significant predictor using the stepwise selection method (2 = education, 3 = physical health rating, 4 = normalized whole brain volume, 5 = gender, 6 = use of a medication that may interfere with cognition). No predictors were removed from the model after meeting the criterion for model entry. AUC = area under receiver operating characteristic curve.
Similar articles
- Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Morris JC, et al. Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269. Arch Neurol. 2009. PMID: 20008650 Free PMC article. - Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O. Leuzy A, et al. JAMA Neurol. 2020 Aug 1;77(8):955-965. doi: 10.1001/jamaneurol.2020.0989. JAMA Neurol. 2020. PMID: 32391858 Free PMC article. - Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A. Grimmer T, et al. J Nucl Med. 2016 Feb;57(2):204-7. doi: 10.2967/jnumed.115.163717. Epub 2015 Nov 19. J Nucl Med. 2016. PMID: 26585056 - Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected].
Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, Ren WD. Ma Y, et al. Medicine (Baltimore). 2014 Dec;93(27):e150. doi: 10.1097/MD.0000000000000150. Medicine (Baltimore). 2014. PMID: 25501055 Free PMC article. Review. - [Amyloid PET in Alzheimer research].
Ishii K. Ishii K. Brain Nerve. 2010 Jul;62(7):757-67. Brain Nerve. 2010. PMID: 20675880 Review. Japanese.
Cited by
- Neuroimaging of dementia in 2013: what radiologists need to know.
Haller S, Garibotto V, Kövari E, Bouras C, Xekardaki A, Rodriguez C, Lazarczyk MJ, Giannakopoulos P, Lovblad KO. Haller S, et al. Eur Radiol. 2013 Dec;23(12):3393-404. doi: 10.1007/s00330-013-2957-0. Epub 2013 Jul 10. Eur Radiol. 2013. PMID: 23839168 Review. - OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE.
Galvin JE. Galvin JE. Neurodegener Dis Manag. 2012 Jun;2(3):291-304. doi: 10.2217/nmt.12.21. Neurodegener Dis Manag. 2012. PMID: 22973426 Free PMC article. - Quantifying and Examining Reserve in Symptomatic Former National Football League Players.
Foley ÉM, Tripodis Y, Yhang E, Koerte IK, Martin BM, Palmisano J, Makris N, Schultz V, Lepage C, Muehlmann M, Wróbel PP, Guenette JP, Cantu RC, Lin AP, Coleman M, Mez J, Bouix S, Shenton ME, Stern RA, Alosco ML. Foley ÉM, et al. J Alzheimers Dis. 2022;85(2):675-689. doi: 10.3233/JAD-210379. J Alzheimers Dis. 2022. PMID: 34864657 Free PMC article. - Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology.
James E, Vielle A, Cusato K, Li H, Lee B, Parween S, Howell A, Johnson NR, Chial HJ, Potter H, Vergara MN. James E, et al. Front Cell Neurosci. 2024 Jan 23;18:1340448. doi: 10.3389/fncel.2024.1340448. eCollection 2024. Front Cell Neurosci. 2024. PMID: 38323188 Free PMC article. - Cardiac sympathetic neuroimaging in dementia with lewy bodies.
Goldstein DS. Goldstein DS. J Neuroimaging. 2012 Apr;22(2):109-10. doi: 10.1111/j.1552-6569.2010.00526.x. Epub 2010 Oct 26. J Neuroimaging. 2012. PMID: 20977534 Free PMC article. No abstract available.
References
- Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138–144. - PubMed
- Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682–1687. - PubMed
- Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol 1999;45:358–368. - PubMed
- Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 AG005681-22/AG/NIA NIH HHS/United States
- U01AG016976/AG/NIA NIH HHS/United States
- R01NS066905-01/NS/NINDS NIH HHS/United States
- P01AG03991/AG/NIA NIH HHS/United States
- R01 DC009095-03/DC/NIDCD NIH HHS/United States
- P01AG003991/AG/NIA NIH HHS/United States
- 5 R01 AG15928-02/AG/NIA NIH HHS/United States
- 1U24RR026057/RR/NCRR NIH HHS/United States
- 1UL1RR024992/RR/NCRR NIH HHS/United States
- 1RC1AG036045-01/AG/NIA NIH HHS/United States
- P50AG005681/AG/NIA NIH HHS/United States
- 1U24RR02573601/RR/NCRR NIH HHS/United States
- 1RC2MD004750-01/MD/NIMHD NIH HHS/United States
- 5U54EB00514905/EB/NIBIB NIH HHS/United States
- 1K12RR024994/RR/NCRR NIH HHS/United States
- P30 CA091842/CA/NCI NIH HHS/United States
- P30-NS048056/NS/NINDS NIH HHS/United States
- 1R01EB009352/EB/NIBIB NIH HHS/United States
- 1UL1RR024992-01/RR/NCRR NIH HHS/United States
- P01-AG03991/AG/NIA NIH HHS/United States
- P01AG026276/AG/NIA NIH HHS/United States
- T32 NS007205/NS/NINDS NIH HHS/United States
- 2P30NS048056-06/NS/NINDS NIH HHS/United States
- 1R01NS055963-01/NS/NINDS NIH HHS/United States
- R01AG16335/AG/NIA NIH HHS/United States
- 1U01AG032438-02/AG/NIA NIH HHS/United States
- U01AG024904/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 NS048056-01/NS/NINDS NIH HHS/United States
- U01AG032438/AG/NIA NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- P30 NS048056/NS/NINDS NIH HHS/United States
- P50-AG05681/AG/NIA NIH HHS/United States
- KL2RR024994/RR/NCRR NIH HHS/United States
- 2P01 AG03991-26/AG/NIA NIH HHS/United States
- U54CA136398-02/CA/NCI NIH HHS/United States
- 5U01AG03243802/AG/NIA NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- 5K12RR023249-03/RR/NCRR NIH HHS/United States
- P50 NS006833/NS/NINDS NIH HHS/United States
- U24AG026395/AG/NIA NIH HHS/United States
- P50NS006833/NS/NINDS NIH HHS/United States
- P50AG05681/AG/NIA NIH HHS/United States
- 3 R01 DK063202-03S1/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical